Inhibrx Shares Jump >20% on Merger Interest

Inhibrx Biosciences stock surged over 20% after Reuters reported takeover interest from Merck, Merck KGaA, and Ono Pharmaceutical.
The interest focuses on INBRX-106, being tested alone and with Merck’s Keytruda, potentially valued above $8 billion.
A joint spin‑off of INBRX-106 and another experimental cancer drug could be worth more than $9 billion if trials succeed.
Talks are in early stages, any deal likely months away, with valuation dependent on upcoming clinical results.